Memphasys (ASX:MEM) will start in vitro utilization testing of its Felix System in China as part of an agreement with Hong Kong-based biotech company Heranova Lifesciences HK, according to a Monday filing with the Australian bourse.
Heranova will conduct testing at Sichuan Jinxin Xinan Women & Children Hospital in Chengdu to assess the usability of the system in routine and challenging in vitro fertilization cases using 50 patient cases, with the company supplying 50 Felix cartridges and one console, the filing said.
The testing will assess the biological performance and health economic benefits of the system, according to the filing.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。